Welcome to the Sun Pharma Stock Liveblog, your ultimate source for real-time updates and analysis of one of the most ...

Sun Pharmaceutical Industries Ltd. closed 4.67% below its 52-week high of 1,869.75 rupees, which the company reached on ...

A trio of Indian drugmakers—Alembic Pharmaceuticals, Sun Pharmaceutical and Glenmark Pharmaceuticals—issued separate voluntary U.S. drug recalls in recent weeks due to either the presence of ...

Welcome to the Sun Pharma Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock.

Sun Pharma's Managing Director, Kirti Ganorkar, predicts that new age medicines for obesity and diabetes will drive the growth of the domestic pharmaceutical industry.

Weak US momentum and regulatory headwinds drag Sun Pharma below Sensex and Nifty despite steady domestic gains ...

Sun Pharmaceutical Industries Ltd is quoting at Rs 1761, up 0.05% on the day as on 12:44 IST on the NSE. The stock is down 4.18% in last one year as compared to a 10.11% gain in NIFTY and a 0.66% gain ...

The Food and Drug Administration recently approved Sun Pharmaceuticals’ metformin hydrochloride tablets to improve glycemic control in adults with Type 2 diabetes. The drug is intended to help control ...

JM Financial has a buy call on Sun Pharmaceutical Industries with a target price of Rs 2115. The current market price of Sun Pharmaceutical Industries is Rs 1655.2. The time period given by the ...

HYDERABAD/BENGALURU Jan 31 (Reuters) - Sun Pharmaceutical (SUN.NS), opens new tab, India's largest drugmaker by revenue, reported a bigger-than-expected quarterly profit on Friday, aided by strong ...

Cipher Pharmaceuticals shares advanced Tuesday after the company said it was awarded 4.2 million Canadian dollars ($3 million) and royalties from its arbitration with Sun Pharmaceuticals Industries.

Sun Pharmaceutical Industries was hit with a patent infringement lawsuit on July 9 in New Jersey District Court over its attempt to market generic versions of the antipsychotic drug Invega Sustenna.